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INTRODUCTION 
Colorectal cancer  is  one  among  the most  common  malignancies 
throughout  the world.  Worldwide   incidence  rate  of  colon  cancer  is  
increasing  to 2%  annually.  Accounts  for  9%  of  all  cancer  incidence. 
Etiology  appears  to  be  multifactorial  which  includes  genetics, 
environmental   factors  and  dietary  factors.  Peak  incidence  is  in  the 
seventh  decade  and  a  male  predominance  is  seen. Sigmoid colon  and  
rectum  are  the   most  commonly  affected  sites. 
Inherited  syndromes  associated  with  increased  risk  of  
colorectal cancer  include  Lynch  syndrome  (formerly  known  as  
hereditary  non-polyposis  colorectal  cancer),  Familial  adenomatosis  
polyposis, Peutz-Jeghers  syndrome  and  PTEN  Hamartoma   syndrome  
(Cowden syndrome).  Chronic  inflammatory  bowel   diseases  
(ulcerative colitis and  crohns  disease)  are  also  associated  with  an  
increased  risk  for colon  cancer. 
               Colorectal carcinomas may be fungating, intraluminal  or  
ulcerating masses. Adenocarcinomas account for more than 90% of 
colorectal carcinomas.  Most common histological pattern is classic 
adenocarcinoma.                                                                                                                                                                                                    
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Other subtypes  are : 
 Mucinous  adenocarcinoma 
 Signet  ring  cell  carcinoma 
 Medullary  carcinoma 
 Serrated  carcinoma 
 Adenosquamous  carcinoma 
 Small  cell  carcinomas  or  neuroendocrine  carcinomas 
The  grading  system  for  colorectal  adenocarcinomas  is  based  
on  the extent  of  well-formed  glands  either  well  differentiated 
(>95%), moderately  differentiated (50-95%)  or  poorly  differentiated 
(<50%). 
Histomorphological  assessment  on  hematoxylin-eosin (H&E)  
stained  sections  remains  the  most  important  diagnostic  tool. 
Immunohistochemistry can  be  used  for  the  diagnosis  and  
prognosis of   colorectal  adenocarcinomas. Various  immunological  
markers  for colon  carcinoma  are  MUCI  and  MUC3,  P53,  CK20,  
CEA,  HER-2/neu,  CD X2,  tumour  associated  glycoprotein,  cathepsin,  
HCG  and PLAP. 
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Human  epidermal  growth  factor  receptor (HER-2/neu)  over  
expression  correlates  with  mitogenesis ,  malignant  transformation , 
invasion  and  metastasis  and  correlates  with  poor  prognosis . HER-2/ 
neu  is  located  on  chromosome  17q21  and  it  encodes  a  185  KD 
transmembrane  protein  . HER-2/neu  activity  initiates  signal  cascades 
including  MAPK (Mitogen  activated  protein  kinase)  and  p13k (AKT 
3 kinase)  pathways  that  are  essential  for cell  proliferation  and 
differentiation. 
The  purpose  of  this  study  is  to  analyze  the  
histomorphological  patterns  and  grades  of  colorectal  adenocarcinoma  
and  to  study immunohistochemical  expression  of  HER-2/ neu  and  its  
correlation  with  clinico  pathologic  variables  and  its  role  in  targeted 
therapy. 
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AIM AND OBJECTIVES 
Aim  is  to  study  the  correlation  between  HER-2/neu  
expression  in  colorectal  adenocarcinoma. 
OBJECTIVES 
 To study  HER-2/neu  expression  in colorectal  adenocarcinomas. 
 To  study  the  correlation  of   HER-2 /neu  expression  with   age, 
sex,  site  and  type  of   tumour. 
 To  study  the  correlation  of  HER-2/neu  expression  with  
histological  grade  of  carcinoma. 
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REVIEW OF LITERATURE 
Colorectal   carcinoma   is  one  of  the  most  deadly  cancer  with  
increased  morbidity  and  mortality  in  the  word.
(1)
  Incidence of 
colorectal  carcinoma  is  9%   and  this  being  the  third  most  common 
cancer  world  wide.
(2)
  Classic  adenocarcinomas   accounts  for  90%  of 
colorectal  carcinomas  and  it  is  the  most  common  type.  Mucinous 
adenocarcinoma,  signet  ring  cell  carcinoma,  medullary  carcinoma, 
serrated  carcinoma, adenosquamous  carcinoma  and  small  cell 
carcinomas account  for  the  remainder  cases. In a study by Manmeet 
Kaur Gill et al (2011) showed that conventional adenocarcinoma 
consitituted about 77.5% followed by mucinous adenocarcinoma 17.5% 
and signet ring cell carcinoma 2.5%.
(3)
  
HISTORICAL HIGHLIGHTS: 
Colorectal  carcinomas  were  not  recognized  as  a  distinct  
disease  until  1960.  Incidence  rates   have  doubled  since  mid  
1970’s.(4)  Incidence  rate  declined  from  mid  1980’s  to  mid 1990’s  
followed  by a  short  period  of  stabilization  . From  1998  to  2005 ,  
incidence  rate  again  declined  – an  average  of  2.8%  per  year  for  
men  and  2.2%  per  year  among  woman.  Mortality   for CRC has 
6 
 
declined over the last 20 years. Between 1985 and 2002 the decline was  
1.8%  per year. 
EMBRYOLOGY : 
The  gastrointestinal  tract  initially  arises  during  the  process  of 
gastrulation   from  the  endoderm  of  the trilaminar embryo  (week 3) 
and  extends  from  the  buccopharyngeal  membrane  to  the  cloacal 
membrane .  Three  distinct  regions – forgut,  midgut  and  hindgut  are 
formed  during  the  4
th
  week .  Colon  and  rectum  are  formed  from  
part  of  midgut  and  hindgut .  Midgut forms ascending colon and 
proximal transverse  colon. Hindgut  forms  distal  transverse  colon, 
descending  colon ,  sigmoid  colon ,  and  rectum. 
ANATOMY : 
Large intestine  is  a  hollow tube  that  make  last  6  feet  of  the  
digestive  tract.  It  consists  of  caecum ,  colon ,  rectum  and  anus.
(5) 
Other  organs  including  spleen ,  pancreas  , liver,  reproductive  and 
urinary  organs  are  next to  colon  and  rectum .  These organs  will  be  
affected  if  colorectal  carcinoma  spreads  beyond  the  large  intestine . 
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Colon consists of four parts 
 (i) Ascending  colon –  starts  at  caecum  goes  upward  along  right  
side   and  joins the  transverse  colon. 
(ii) Transverse  colon  connects  ascending  colon  and  descending 
colon  and  is  across  the  upper  abdomen. 
(iii) Descending  colon  –  is  between  transverse  colon  and  sigmoid  
colon  and  is  on  the  left  side  of  the  body. 
(iv) Sigmoid  Colon -  connects   descending  colon  and  rectum  and  
is  on  the  left  side. 
Hepatic flexure  is  the  junction  of  ascending  colon  and  transverse  
colon  and  splenic  flexure  is  the  junction  of  transverse  colon  and  
descending  colon .  Rectum  is  the  distal  8- 15 cm  of  large  bowel  and  
it  ends  at anal  canal. 
Layers of colon and rectum : 
Colon and rectum are made   up of  four  layers . They are  
- Mucosa 
- Submucosa 
- Muscularis propria 
- Serous layer 
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1. MUCOSA : 
It   is  the  inner  lining  of  intestine  and  it  is  formed  by  
epithelium , lamina  propria  (connective  tissue)  and  thin  layer  of 
muscle (Muscularis  mucosa). 
The  epithelium  of  the mucosa  is lined  by  single layer  of  
cuboidal  to  low  columnar  cells  in  which  is  the  opening  of  the 
crypts of LieberKuhn  either  into  the  grooves  or  on  the  surface.
(6)
  
The epithelium  has  two  types  of  cells, the  absorptive  cells  which  
have  apical  striated  borders  directed  towards  the  lumen  with  
acidophilic cytoplasm  basally  located  nuclei .  The  other  cell  is  the  
goblet  cell which  synthesize ,  store  and  secrete  mucin  granules .  
Crypts  are  tubular  shaped  and  are  parallel  to  one  another .  The  
crypts  in  addition  to  the  absorptive  cells  and   goblet  cells  also  
contain immature  precursor  cells , endocrine cells  and  Paneth  cells .  
Paneth cells  have  many  eosinophilic  secretory  granules  that  contain 
lysozyme ,  epidermal  growth  factor  and  other  substances . Normally 
they  are  seen only in  caecum  and  proximal  right  colon. 
Lamina  propria  contains  some  lymphocytes,  plasma  cells,  
histiocytes and  mast  cells  in  a  network  of  collagen  fibers  ,  smooth  
muscle  bundles,  vessels,  and  nerves.  Lymphoglandular  complexes 
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(microbursae)  are  structures   which  are  normally  seen  extending  
from  mucosa  through  mucularis  mucosae  into  submucosa. They  are 
formed  by  deep  crypt  epithelium  which  are  surrounded  by  lymphoid  
follicles . 
Muscularis  mucosae  is  made  up  of  thin  layer  of  smooth  
muscle fibers  and  this  separates   submucosa  from  mucosa. 
2. SUBMUCOSA : 
It  is  made  up  of  connective  tissue ,  glands ,  lymphatic  vessels, 
blood  vessels  and  nerves. 
3. MUSCULARIS PROPRIA : 
It  is  the  muscle  layer  made  up of  longitudinal  outer  layer  and  
circular  inner  layer. 
4. SEROUS LAYER : 
It  is  made  of  single  layer  of  flattened  to  cuboidal  mesothelial  
cells and  fibro  elastic  tissue . 
Part of   the colon is connected to the abdominal wall by mesentry. 
The upper two-third of rectum is covered by mesentry called 
mesorectum.  The  mesentry  is  made  up  of  fatty  connective  tissue  
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that  contain   nerves,  blood  vessels,  lymph  nodes  and  lymphatic 
vessels  that  supply  the  colon. 
NERVE SUPPLY: 
Large  intestine  contains  two  types  of  nerve  plexus.  They are 
- Meissner neural plexus 
- Myenteric neural plexus of Auerbach 
Submucosa  contains  the  neural  plexus  of  Meissner  and  Myenteric 
neural  plexus  of  Auerbach  is  seen  between  the  longitudinal  and 
circular  muscular  layers. 
BLOOD SUPPLY : 
Caecum  to  splenic  flexure  is  supplied  by  branches  of  superior 
mesenteric  artery  and  distal  to  splenic  flexure  is  by  the  inferior 
mesenteric  artery.  Branches  of  internal  iliac  arteries  that  is  middle 
and  inferior  rectal  arteries  supply  lower  portion  of  rectum. 
LYMPHATIC DRAINAGE : 
The  lymphatic  vessels  of  ascending  colon  ends  in  ileocolic  
nodes  and  those  of  transverse  colon  end  in  right  colic  and  middle  
colic nodes.  All these end in superior mesenteric nodes. Lymphatic 
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vessels  of  descending  colon  reaches  left  colic nodes and  those  of 
sigmoid  colon  ends  in  sigmoid  nodes.  These nodes end in inferior 
mesenteric nodes.  Lymphatic  vessels  from  upper  half  of  rectum  
reach  pararectal  nodes  and  ends  in  inferior  mesenteric  nodes . Lower 
half   of lymphatic vessels reach internal iliac nodes. 
FUNCTION: 
Main  functions  of  colon  and  rectum  are  to  absorb  nutrients  
and  water  from  food  and  move  food  waste  out  of  body  by  
movement  ie  peristalsis . 
EPIDEMIOLOGY  : 
Colorectal carcinoma peaks at 60 to 70 years of age. In a study by 
Nekalson et al (2008)  showed that mean age of colorectal carcinoma was 
55.7 years.
(7)
  20%  of  cases occur  before  40  years  and  they  usually  
have  an  inherited predisposition.  Males are slightly more often affected 
than females. In a study by Dalal A.Elwy showed that 60% were males 
and 40% were females.
(8) 
It  is  most  prevalent  in  developed  countries  
than  the  developing  countries . According to U.S.  SEER  database ,  
incidence  rate  for adenocarcinoma  of  colon  is  33.7/100, 000  and  that  
of  rectal adenocarcinoma  is  12.8/100, 000.  Incidence and  mortality  
have  reduced  in  the  last  decade. 
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ETIOLOGICAL FACTORS : 
NON MODIFIABLE RISK FACTORS : 
1. Age 
Diagnosis of colorectal cancer progressively increases from 40.
(9)
 
2. Adenomatous polyps 
Tubular adenomas and villous adenomas are precursor lesions of 
colorectal cancer. 
(10)
 Nearly  95%  of  sporadic  colorectal  cancers  
develop from  these  adenomas .
(11)
  Long  latency  period  of  5  to  10  
years  is required  for  occurrence  of   malignancy  from  these  
adenomas.
(12) 
3. Inflammatory Bowel disease 
It includes two diseases 
a) Ulcerative  colitis  which  causes  inflammation  of  mucosa  of  
colon and  rectum. 
b) Crohn’s   disease causing inflammation of full thickness of bowel 
wall. 
c) Risk of  developing  colorectal  cancer  in  these  conditions  is  
estimated between  4  to  20  fold.
(13) 
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4. Family history of Colorectal cancer or adenomatous polyp 
Colorectal cancer develops in 20% of people who have family 
members with either colorectal cancer or adenomatous polyps.
(14) 
5. Genetic factors  
Colorectal carcinoma is seen in association with the following 
inherited conditions. 
a) Familial adenomatous polyposis 
This occurs due to mutation in APC gene which is a tumour 
suppressor gene located on chromosome 5q21 and this has an autosomal 
dominant inheritance. In a study by Wilmink A BM it is seen that FAP 
accounts for <1% of colorectal cancers.
(15) 
b) Hereditary Non-polyposis colorectal cancer (Lynch syndrome) 
Occurs due to mutation in MLH1 and MSH2 genes which are 
involved in DNA repair pathway.
(16)
 Accounts for 2 % of colorectal 
cancers.  
These mutations results in microsatellite instability. These 
colorectal carcinomas are usually associated with young age, involvement 
of proximal colon, mucinous features and tumour- infiltrating 
lymphocytes. 
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Other less common inherited syndromes associated with colorectal 
carcinoma are Peutz- Jegher’s syndrome, Turcot syndrome,Cowden’s 
syndrome and Torre-Muir syndrome. 
MODIFIABLE LIFESTYLE RISK FACTORS : 
1. Dietary factors : 
Colorectal cancer occurs due to low intake of unabsorbable 
vegetable fibers and high intake of refined carbohydrates and fat. 
Reduced fiber content leads to decreased stool bulk and altered 
composition of intestinal microbiota which increase synthesis of toxic 
oxidative by products of bacterial metabolism which in contact with 
colonic mucosa cause damage. High fat intake enhances hepatic synthesis 
of cholesterol and bile acids which are converted by bacteria in the 
intestine to carcinogens.
(17) 
2. Physical inactivity and obesity: 
Physical inactivity and excess body weight are associated with 
colorectal cancer.
(18) 
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3. Smoking : 
Cigarette smoking leads to the formation of adenomatous polyps 
which are the precursor lesions of colorectal cancer.
(19)
 Those among who 
smoke, there is earlier age of onset of cancer.
(20) 
4. Alcohol consumption : 
Alcohol consumption is associated with increased risk of 
developing colorectal cancer.In a study by Tsong WH et al it is seen that 
colorectal cancer in alcoholics is associated with a younger age.
(21) 
Mechanisms of developing colorectal carcinoma is that 
acetaldehyde and other reactive metabolites of alcohol may be 
carcinogenic. It also acts as a solvent for penetration of other carcinogens. 
It is also mediated by production of free radical oxygen species .
(22) 
5. Irradiation: 
Therapeutic pelvic irradiation is associated with development of 
colorectal carcinoma. 
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PATHOGENESIS : 
Two genetic pathways have been described. 
1. APC/B-Catenin pathway which is associated with WNT and 
classic adenoma – carcinoma sequence. 
2. Microsatellite instability pathway in which there is defects in DNA 
mismatch repair. 
CLASSIC ADENOMA –CARCINOMA SEQUENCE 
This accounts for 80% of sporadic colon tumours. Mutation of 
APC gene which is a tumour suppressor gene occurs early in the 
neoplastic process. Tumour occurs when both the copies are functionally 
inactivated. APC is a negative regulator of beta catenin which is a 
component of WNT signaling pathway. Beta catenin accumulates when 
there is loss of APC function and this translocates to nucleus and 
activates transcription of MYC and Cycle D1 genes which promote 
proliferation of cells. 
Additional mutations are followed such as activating mutation of 
KRAS which promote growth and prevent apoptosis. Mutation of tumour 
suppressor genes SMAD2 and SMAD4 occurs which are effectors of 
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transforming growth factor beta signaling which normally inhibits cell 
cycle. Also there is loss of function of P53 which controls the cell cycle. 
All these mutations occur due to chromosomal instability. 
MICROSATELLITE INSTABILITY PATHWAY: 
In DNA mismatch repair deficiency there is microstatellite 
instability ie mutation in micro statellite repeats. Some of these repeats 
are in the coding or promoter region of genes such as type II transforming 
growth factor beta receptor and pro-apoptotic protein BAX which are 
involved in regulation of cell growth. Transforming growth factor beta 
inhibits colonic cell proliferation and hence its mutation leading to 
uncontrolled cell growth and mutation in BAX leads to survival of 
genetically abnormal clones. 
CLINICAL FEATURES 
Colorectal cancers are seen insidiously and are asymptomatic in 
some patients. Common presenting features are hematochezia and 
anaemia. 
Right sided colon cancers produce symptoms like fatigue and 
weakness due to iron deficiency anaemia. Left sided colon cancers 
produced symptoms like occult bleeding, change in bowel habits with 
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alternate constipation and diarrhoea, left quadrant discomfort or 
abdominal pain. Intestinal obstruction is commonly seen with left sided 
colon tumour. Rectosigmoid tumours produce tenesmus. 
DIAGNOSTIC PROCEDURES 
Imaging : 
Early detection of colorectal carcinoma has increased over past few 
decades with the use of CT and screening studies in asymptomatic 
populations. CT is superior to conventional barium enema in detecting 
colorectal tumours. CT, MRI imaging and transrectal ultrosonography 
help in the assessment of depth and margins of the tumour and to detect 
regional and distant metastases. Scintigraphy and positron emission 
tomography are also used.
(23) 
TISSUE SAMPLING PROCEDURE : 
Colonoscopic and sigmoidoscopic biopsy is the definite method for 
establishing a diagnosis of colon and rectal lesions 
Indications of colonoscopy 
1. Colorectal carcinoma screening in high risk people 
2. Evaluation and removal of polyps 
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3.  Current or previous bowel resection for colon cancer 
4. Family history of cancer 
5. Management of inflammatory bowel disease 
6. Identification of acute bleeding sites 
7. Decompression of colon 
IMMUNOHISTOCHEMISTRY: 
Immunohistochemistry is a adjuvant technique which is commonly 
used to diagnose colorectal tumours. Immunohistochemistry has largely 
replaced mucin histochemistry and electron microscopy in diagnosing 
tumours of colon and rectum because of relative ease of use and 
specificity. 
Markers in colorectal carcinoma 
The various immunohistochemical markers for colon carcinoma are 
1. MUC1 and MUC3 
2. P53 
3.  Cytokeratin 20 
4. Carcino embryonic antigen 
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5. HER-2/ neu – Epidermal growth factor receptor 
6. CDX2 
7. TAG-72-Tumour associated glycoprotein 
8. Cathepsin 
9. Villin 
10. HCG 
11. PLAP- Placental Alkaline Phosphatase 
MUC-1 and MUC-3 
Mucins are glycoproteins which are expressed by many epithelial 
cells. They are also expressed in some of their malignant counterparts. 
Their expression can be used as prognostic indicator and also their use in 
cancer therapy. 
There are several mucins such as MUC1, MUC2, MUC3, MUC4, 
MUC5 AC and MUC6.   A study by Cao Y et al showed that MUC-1 and 
MUC3 are more commonly expressed in conventional colorectal 
carcinomas. 
(24)  
MUC2 expression is mostly seen in mucinous 
carcinomas. MUC13 expression is seen particularly in poorly 
differentiated tumours. 
21 
 
Mucins are also expressed in many other malignancies such as 
breast carcinoma, pancreatic and gastric carcinoma. In colorectal 
carcinoma there is usually no expression of MUC5AC which is 
commonly expressed in pancreato biliary tumours. 
CYTOKEROTIN 20 
Cytokeratin 20 is a protein found in mature enterocytes and goblet 
cells and it is a protein which is specifically found in gastric and intestinal 
mucosa .
(25)
 It is encoded by the gene KRT20 in humans.
(26)
 Colorectal 
adenocarcinomas are positive for cytokeratin 20  invariably.
(27) 
Positivity with CK 20 is also found in transitional cell carcinomas 
and in Merkel cell carcinoma. Positivity with cytokeratin 20 and 
negativity for cytokeratin 7 is the most common pattern and is used to 
differentiate colorectal adenocarcinomas from adenocarcinomas of lung, 
ovary and prostate.
(28) 
CARCINOEMBROYONIC ANTIGEN : 
Carcinoembroyonic antigen are glycosyl phosphatidyl inositol cell 
surface anchored glycoprotein involved in cell adhesion.It is normally 
produced during fetal development in gastro intestinal tissue and its 
production stops before birth. 
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But in certain cancers such as colorectal carcinoma, gastric 
carcinoma, pancreatic carcinoma, lung carcinoma, breast carcinoma, 
medullary thyroid carcinoma and in certain non neoplastic conditions like 
ulcerative colitis, pancreatitis , cirrhosis, COPD, Crohn’s disease and 
hypothyroidism expression of CEA and its serum levels are increased.
(29)
 
And therefore it is used as tumour marker in these tumours. 
HER-2/ NEU 
Human epidermal growth  factor receptors are G-protein receptors 
which when activated stimulate multiple signal transduction pathways 
which are involved in regulation of cellular growth. HER 1(EGFr), 
HER2(Her-2neu or ERB2),HER3 and HER4 are the HER family of 
receptors. Of these HER- 2 amplification and overexpression has been 
seen in certain tumours like breast cancer, colorectal cancer, oesophageal 
carcinoma, gastric carcinoma and ovarian tumours. 
HER - 2 is located on chromosome 17q21. It encodes a 185KD 
transmembrane protein. Its activation initiates pathways that are 
important for cell proliferation and differentiation such as MAPK-
Mitogen activated protein Kinase and P13K/AK7 (3 Kinase) pathways. In 
recent years this protein is used an important tumour marker and is also 
used as a target of therapy. 
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P53 
P53 is a tumour suppressor protein encoded by TP53 gene located 
on short arm of chromosome 17.
(30)
 The function of P53 protein is that it 
can arrest cell cycle at G1/S regulation point when it recognizes DNA 
damage and its activates DNA repair protein which help to correct the 
damage. If DNA damage is irreparable it will initiate apoptosis of the 
affected cell. It has been found that TP 53 gene is most frequently 
mutated gene in most human cancers. 
Colorectal carcinomas commonly involves P53 mutation which 
leads to mutated  P53 protein expression in tumour cells. Its expression is 
found to be associated with poor prognosis and reduced survival. 
CDX2 
CDX2 is a homeobox gene which encodes a transcription factor 
that takes part in proliferation and differentiation of intestinal epithelial 
cells. It is found to be expressed in majority of colorectal 
adenocarcinoma.
(31) 
 In a study by Mazziotta RM et al showed that CDX2 
was  also expressed in mucin producing carcinomas of ovary, lung, 
bladder and pancreatobiliary adenocarcinomas.
(32) 
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TAG-72 
Tumour associated glycoprotein 72 is a glycoprotein found on 
surface of many cancer cells including breast, ovary, colon, and 
pancreatic cells.
(33) 
 It is present in 100% of invasive colorectal tumours. 
It is also found in hyperplastic and adenomatous polyp and also in normal 
mucosa. The pattern of expression and frequency of reactivity vary 
depending on the conditions.
(34) 
CATHEPSIN B 
Cathepsin B is a lysosomal cysteine protease coded by the CTSB 
gene.
(35) 
It is found expressed in colorectal carcinomas and in wide array 
of disease. 
VILLIN 
Villin is a actin-binding protein found associated with actin core 
bundle of brush border of microvilli.
(36)
 It is expressed in colorectal 
adenocarnimas . 
HUMAN CHORIONIC GONADOTROPIN 
Human Chorionic gonadotropin is a hormone produced by syncytio 
trophoblast. It is elevated in some cancerous conditions. 
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Colorectal adenocarcinomas show increased expression of HCG 
and mostly seen in mucinous and poorly differentiated tumours.
(37) 
PLACENTAL ALKALINE PHOSPHATASE 
Placental alkaline phosphatase is an enzyme encoded by ALPP 
gene.
(38)
 PLAP is a tumour marker for seminoma and ovarian cancer.  
Also seen in 10% of Colorectal carcinoma. 
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF                         
COLON AND RECTUM 
EPITHELIAL TUMOURS 
Adenoma 8140/0 
 Tubular 8211/0 
 Villous 8261/0 
 Tubulovillous 8263/0 
 Serrated 8213/0 
Intraepithelial neoplasia (dysplasia) 
Associated with chronic inflammatory diseases 
 Low-grade glandular intraepithelial neoplasia 
 High-grade glandular intraepithelial neoplasia 
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Carcinoma 
 Adenocarcinoma 8140/3 
 Mucinous adenocarcinoma 8480/3 
 Signet-ring cell carcinoma 8490/3 
 Small cell carcinoma 8041/3 
 Squamous cell carcinoma 8070/3 
 Adenosquamous carcinoma 8560/3 
 Medullary carcinoma 8510/3 
 Undifferentiated carcinoma 8020/3 
Carcinoid (well differentiated endocrine neoplasm) 8240/3 
 EC-cell, serotonin-producing neoplasm 8241/3 
 L-cell, glucagon-like peptide and PP/PYY producing tumour 
 Others 
Mixed carcinoid-adenocarcinoma 8244/3 
Others 
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NON-EPITHELIAL TUMOURS 
 Lipoma 8850/0 
 Leiomyoma 8890/0 
 Gastrointestinal stromal tumour 8936/1 
 Leiomyosarcoma 8890/3 
 Angiosarcoma 9120/3 
 Kaposi sarcoma 9140/3 
 Malignant melanoma 8720/3 
 Others 
Malignant lymphomas 
 Marginal zone B-cell lymphoma of MALT Type 9699/3 
 Mantle cell lymphoma 9673/3 
 Diffuse large B-cell lymphoma 9680/3 
 Burkitt lymphoma 9687/3 
 Burkitt-like /atypical Burkitt-lymphoma 9687/3 
 Others 
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SECONDARY TUMOURS 
Polyps 
Hyperplastic (metaplastic) 
Peutz-Jeghers 
Juvenile 
PRECURSOR LESIONS : 
1. Aberrant crypt foci 
2. Adenomas 
3. Hyperplastic polyps 
4. Juvenile polyp 
5. Inflammatory polyps 
6. Chronic inflammatory bowel disease 
Aberrant crypt foci: 
Aberrant crypt foci are the earliest morphological precursor of 
epithelial neoplasia. Microscopically they have thickened epithelium with 
enlarged calibre and reduced mucin content. 
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There are two main types 
1.  Aberrant crypt foci with features of hyperplastic polyps. 
   RAS protooncogene mutations are seen in high frequency. 
2.  Dysplastic Aberrant crypt foci (Micro-adenomas) 
Mutation of APC gene is seen 
     Carcinogenesis in large intestine is characterized by progression from 
ACF through adenoma to carcinoma.
(39) 
 This was also observed in a 
study by  Nascimbeni R et al.
(40)
  
Adenomas : 
Adenomas are precursor lesions defined by the presence of 
intraepithelial neoplasia. It is histologically characterized by increase in 
cellularity, enlarged hyper chromatic nuclei, nuclear stratification and 
loss of polarity. They can be low grade or high grade which depends on 
degree of villous or glandular complexity, extent of nuclear stratification, 
and severity of nuclear morphology. 
Macroscopically adenomas are classified into three groups. 
1. Elevated adenoma - ranges from pedunculated to sessile adenomas. 
2. Flat adenomas 
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3. Depressed adenomas 
Histopathologically they are divided into 
1. Tubular adenomas 
2. Villous adenomas 
3. Tubulo villous adenomas 
Tubular adenomas 
They are usually spherical and pedunculated or flat lesions. 
Microscopically 80% of luminal surface is occupied by dysplastic 
glandular structures. 
Villous adenomas 
They are typically sessile with hairy appearing surface. 
Microscopically 80% of luminal surface is lined by leaf like projections 
lined by dysplastic glandular epithelium. 
Tubolovillous adenoma 
Mixture of  both tubular and villous structures are seen. 
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Serrated Adenomas: 
Serrated Adenomas are hyperplastic polyp characterized by saw-
tooth configuration. The upper portion of crypts and luminal surface are 
lined by epithelium having dysplastic changes. 
Hyperplastic Polyps 
Hyperplastic polyps is a mucosal excrescence characterized by 
elongated, crypts which are lined by proliferative epithelium in the bases. 
It has a saw tooth outline due to infolded epithelial tufts and enlarged 
goblet cells in the upper crypts and on luminal surface. The nuclei of 
epithelial cells are small regular round and located at base of cells with 
cytoplasm having prominent mucin. 
Juvenile Polyps 
These are usually seen in children. They can occur either 
sporadically or genetically. Sporadic juvenile polyps are spherical, 
lobulated and pedunculated. Microscopically they have abundant stroma 
composed of granulation tissue which is inflamed and oedematous and it 
surrounds cystically dilated glands lined by cuboidal to columnar cells 
with reactive changes and they contain mucin. Polyps in juvenile 
polyposis syndrome have frond like pattern with more proliferative small 
glands and few dilated glands and stroma. 
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Inflammatory polyps : 
These polyps have reactive epithelium, inflamed granulation tissue 
and fibrous tissue in varying proportions. These polyps are seen in 
chronic inflammatory bowel disease and diverticulitis. 
Chronic inflammatory bowel disease : 
Chronic colitis is associated with colorectal carcinomas .Chronic 
colitis is seen in ulcerative colits and crohns disease. 
ADENOCARCINOMA 
Conventional adenocarcinomas account for more than 90% of 
colorectal carcinomas. Sigmoid and rectum are most commonly affected 
sites.  In a study by Slater G etal it was seen that in elderly patients and in 
diverticular disease right sided tumours are most common.
(41) 
Macroscopy: 
Macroscopically colorectal carcinomas can be of the following types: 
a. Exophytic/fungating -Intraluminal growth predominantly.                          
Exophytic masses are usually seen in proximal colon carcinomas. 
b. Endophytic/ ulcerative –Intramural growth predominantly 
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c. Diffusely infiltrative / linitis plastica 
d. Annular – circumferential involvement of colorectal wall and leads 
to constriction of lumen. 
Endophytic  masses and annular growth as usually seen in carcinomas of 
transverse colon and descending colon. 
Cut section: 
On cutsection colorectal carcinomas have homogeneous grayish 
white tissue that replaces the bowel wall. Areas of necrosis can be seen. 
Tumour is seen either confined to the wall or extended into pericolic 
tissues. 
Microscopy : 
Conventional adenocarcinomas is characterized by glandular 
formation. Depending on the gland formation tumour has been classified 
into following types. 
a. Well-differentiated adenocarcinoma – gland formation is seen in 
more than 95% of the tumour. 
b. Moderately differentiated adenocarcinoma – 50-95% of the tumour 
shows gland formation. 
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c. Poorly differentiated adenocarcinoma <50% of the tumour shows 
gland formation. 
Most common colorectal adenocarinomas are well to moderately 
differentiated adenocarcinomas. Well differentiated tumour show well 
formed glands lined by tall columnar cells with abundant eosinophilic 
cytoplasm and basally located nuclei with mild atypia. Mitotic figures are 
less frequent. 
Moderately differentiated tumours show haphazardly arranged 
imperfectly formed glands lined by tumour cells showing moderate 
atypia. Mitotic figures are variable. 
Poorly differentiated tumours show solid sheets of tumour cells 
which show marked atypia. Mitosis is more frequent. 
Colorectal adenocarcinomas are said to be invasive when they 
invade through muscularis mucosae into submucosa.  Other features of 
invasiveness are presence of desmoplasia or demoplastic reaction which 
is a type of fibrous proliferation seen surrounding the tumour cells and 
the presence of necrotic debris in glandular lumina called dirty necrosis. 
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Variants: 
1. Mucinous adenocarcinoma 
Mucinous adenocarcinomas constitute of about 15% of colorectal 
carcinomas. They are most commonly seen in the rectum. 
Macroscopically they usually have an exophytic growth with grossly 
visible mucin. Only when more than 50% of the tumour is composed of 
mucin it is called as mucinous adenocarcinomas. When the mucinous 
component is >10% but <50% it is termed as adenocarcinoma with 
mucinous features or differentiation. 
Tumour is characterized by pools of extracellular mucin that 
contain malignant epithelial cells as acinar structures, strips of cells or 
single cells. Mucinous adenocarcinoma shows high rate of microsatellite 
instability.  Prognosis of mucinous adenocarcinoma is poor when 
compared with conventional adenocarcinoma. 
Signet ring carcinoma: 
Signet ring carcinoma is also called as Linitis Plastica-type 
carcinoma. Signet ring carcinoma is a rare variant of colorectal 
carcinoma. It is commonly seen in young patients. Grossly it most 
commonly presents as diffuse infiltration of bowel wall but also arise in 
adenomatous polyp.
(42)(43) 
36 
 
Microscopically cells may be arranged in diffuse sheets, nests or 
infiltrative cords. The signet ring cell has a large mucin vacuole that fills 
the cytoplasm and displaces and compresses the nuclei to the periphery. 
Signet ring cell carcinoma is defined only when more than 50% of 
cells in the tumour have intracytoplamic mucin.
(44)
 These cells can occur 
in diffuse infiltrative pattern with minimal extra cellular mucin or in 
pools of mucin in mucinous adenocarcinoma. Metastasis occur in 
lymphnode, ovary and peritoneal surface. Prognosis is poor.
(45) 
Micro papillary variant: 
This is seen in 20% of colorectal adenocarcinomas. It is associated 
with increased frequency of lymphovascular invasion and lymph node 
metastases and therefore it has poor prognosis.
(46) 
Serrated adenocarcinoma: 
Serrated adenocarcinomas comprise 7.5% of all colorectal tumours. 
It is presumed to arise from serrated adenoma.
(47)
 Pattern of growth seen 
is serrated, mucinous or trabecular. Cells have abundant eosinophilic 
cytoplasm, chromatin condensation with preserved polarity.
(48) 
 
 
37 
 
Adenosquamous carcinoma:  
These are rare tumours showing both squamous carcinoma and 
adenocarcinoma features. They can be seen either as admixed within the 
tumour or can be seen as separate areas. This carcinoma can be seen 
anywhere in the large bowel but more common in the caecum.
(49)(50)
 The 
squamous differentiation must be more than just occasional small foci for 
the tumour to be classified as adenosquamous. Pure squamous cell 
carcinoma is very rare. 
Medullary carcinoma: 
This rare variant is mostly seen in right colon and is more common 
in females. This is characterized by malignant cells arranged in sheets 
having abundant eosinophilic cytoplasm with vesicular nuclei and 
prominent nucleoli. It exhibits prominent intraepithelial lymphocytic 
infiltration.
(51)
 They have a favourable prognosis. 
Other rare variants: 
Spindle cell or sarcomatoid variant: 
           This variant is composed of spindle cells and are focally 
immunoreactive for cytokeratin. 
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Carcinosarcoma : 
This contains both carcinomatous and heterologous mesenchymal 
elements. 
Clear cell variant: 
They have clear cytoplasm due to accumulation of glycogen.
(52) 
Anaplastic (Pleomorphic, giant cell) variant
 
Trophoblastic variant
(53) 
Basaloid  variant
(54) 
Hepatoid differentiation 
Glassy Cell variant
(55) 
Rhabdoid variant
(56) 
Oncocytic variant 
Neuroendocrine differentiation 
This can occur in the following ways. 
a)  As scattered endocrine cells in a mucinous adenocarcinoma.In a 
study Bosman FT also found these cells scattered in mucinous 
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adenocarcinoma.
(57)
 This occurs most commonly after 
chemotherapy or radiotherapy and it does not affect the prognosis . 
b) As mixed composition with both adenocarcinomatous component 
and endocrine differentiation.
(58) 
c)  Occurs with predominantly neuroendocrine differentiation which 
can be either large cell or small cell neuroendocrine carcinoma. 
STAGING : 
There are many staging systems for colorectal carcinoma. 
- Duke’s Classification 
- Staging system of Astler and Collar 
- Staging system by American Joint Commmittee 
- TNM Classification of staging 
1. Duke’s Classification 
This classification was proposed on 1937.
(59) 
This staging method is 
simplest and is directly related to prognosis. 
Stage A – only the wall of the bowel is involved by the tumour. 
Stage B - Tumour extends through the bowel wall. 
Stage C - Tumours having lymphnode metastases. 
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Modificaitons were proposed and further subclassified stage-C to C1 and 
C2 and also included stage D. 
Stage C1- Where only regional lymph nodes were involved. 
Stage C2- Involvement of nodes at mesenteric blood vessels.
(60) 
Stage D - which indicates distant metastasis. 
2. Astler and Coller classification 
This classification was proposed in 1954.
(61) 
Stage A - Tumour limited to mucosa. 
Stage B1 - Tumour involves muscularis externa but does not 
penetrate through it. 
Stage B2 - Tumour penetrates through muscularis externa. 
Stage C1 - Tumour is confined to bowel wall with nodal 
metastases. 
Stage C2 - Tumour penetrates through the bowel wall with 
nodal metastases. 
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3. TNM Classification : 
This classification now seems to replace Duke’s Classification.(62) 
T – Primary Tumour 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1  Tumour invades submucosa 
T2  Tumour invades muscularis propria 
T3  Tumour invades through muscularis propria into subserosa or into 
non-peritonealized pericolic or perirectal tissues 
T4  Tumour directly invades other organs or structuresand/or perforates 
visceral peritoneum 
N – Regional Lymph Nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in 1 to 3 regional lymph nodes 
N2  Metastasis in 4 or more regional lymph nodes 
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M – Distant Metastasis 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
Stage Grouping 
Stage 0  Tis   N0   M0 
Stage I  T1   N0   M0 
T2   N0   M0 
Stage II  T3   N0   M0 
T4   N0   M0 
Stage III  Any T  N1   M0 
Any T  N2   M0 
Stage IV  Any T  Any N  M1 
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SPREAD AND METASTASIS : 
The tumour can spread in the following ways : 
1. Direct spread 
2. Lymphatic spread 
3. Hematogenous spread 
Direct Spread : 
Tumour involve contiguous structures by direct extension through 
muscularis propria into pericolic or perirectal soft tissues. 
Depending upon the anatomic site will be the consequences of 
direct extension. 
LYMPHATIC SPREAD : 
Regional lymph nodes are the common site of metastatic 
involvement. Lymphatic spread occurs only when muscularis mucosae is 
breached and when there is involvement of submucosa eventhough there 
is presence of lymphatics in the mucosa. Lymph node metastases has 
great prognostic significance and hence there must be thorough search for 
lymphnodes. Minimum number of 14 or 15 nodes must be recovered 
from surgical specimen of colorectal carcinoma.
(63)
 Pericolonic tumour 
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deposits are isolated tumour nodules. These are seen beyond muscularis 
propria in perineurial, perivascular or intravascular location. These must 
be distinguished from lymph node metastasis.
(64) 
HEMATOGENEOUS SPREAD: 
Hematogeneous spread occurs through invasion of tributaries of 
portal vein in colon and tributaries of vena cava in rectum.  Most 
common site of metastasis is liver. In a study by Inada K et al   liver was 
found to be common site of metastasis.
(65)
 Peritoneum, lung and ovaries 
are other metastatic sites which are relatively common. 
Central nervous system, bone, testis, uterus and oral cavity are 
metastatic sites which are rare.
(66)(67) 
GRADING 
Depending on the extent of glandular formation, tumours are graded. 
Grade I -- Well differentiated 
Grade II -- Moderately differentiated 
Grade III -- Poorly differentiated 
Grade IV -- Undifferentiated 
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Mucinous and signet ring carcinomas are considered as grade III (Poorly 
differentiated grade). Medullary carcinoma is considered as grade IV 
(undifferentiated grade). 
Grading can also be done as 
Low-grade which includes well and moderately differentiated 
carcinomas. High grade which includes poorly differentiated and 
undifferentiated tumours. 
TREATMENT 
Surgical resection is the standard therapy for colorectal 
carcinomas. Depending on the site of tumour is the type of surgery.
(68)
  
Ileocolectomy is done for carcinoma  of caecum or ascending colon. 
Abdominoperineal resection done for tumours below peritoneal 
reflection.
(69)
 Anterior resection is done for tumours in other areas of 
large bowel. For small rectal tumours or those who are not fit for 
abdonimoperineal resection other alternative procedures such as 
fulguration, endoscopic transrectal resection and full thickness local 
excision are done.
(70)(71)
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PROGNOSIS 
Number of clinical and pathologic parameters determine the 
prognosis of colorectal carcinoma.
(72) 
AGE : 
Age has important role in rectal tumours than colonic tumours. 
Very young and very old patients have poor prognosis.
(73) 
SEX: 
          Females have better prognosis than males. 
CEA SERUM LEVELS: 
Adverse impact on prognosis is seen when CEA levels are more 
than 5ng/ml.
(74) 
TUMOUR LOCATION: 
Tumours have favourable prognosis when they are situated in left 
colon. Worst outcome is seen in tumours located at sigmoid colon and 
rectum.
(75) 
TUMOUR SIZE:  
Both large and small tumour size have poor prognosis.
(76) 
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TUMOUR EDGE : 
Polypoid tumours have good prognosis when compared with non-
polypoidal tumours. 
TUMOUR MARGIN AND INFLAMMATORY REACTION : 
Tumours   having pushing margins have better prognosis. Presence 
of inflammatory infiltrate at the interphase between tumour and nearby 
tissue has better prognosis. 
LOCAL EXTENT : 
Tumours restricted to mucosa and submucosa have good prognosis 
whereas tumour involving the whole bowel wall or perforation have 
worse prognosis. 
TUMOUR BUDDING : 
At the invasive front if there are isolated tumour cells or clusters of 
more than 5 cells indicates poor outcome.
(77) 
VASCULAR INVASION : 
When there is presence of vascular invasion the incidence of 
distant metastasis is increased and hence the survival is reduced thus 
indicating poor prognosis. Tumour involving the extramural blood 
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vessels is of more prognostic significance than when it involves the 
vessels within the bowel wall. 
PERINEURIAL INVASION : 
This indicates advanced disease and has worst prognosis. 
PERICOLONIC TUMOUR DEPOSITS : 
Presence of pericolonic tumour deposits have poor prognosis.
(78) 
SURGICAL MARGIN : 
In rectal carcinoma involvement of radial margin indicates poor 
prognosis and also predicts local recurrence. 
MICROSCOPIC TYPE AND PATTERN : 
Medullary carcinoma has good prognosis. Mucinous carcinoma, 
signet ring carcinoma and anaplastic carcinoma have worst prognosis. 
Microacinar pattern has worse prognosis. 
GENETIC FACTORS : 
Tumours have poor prognosis when there is expression of mucin 
related antigens such as sialyl-TN and sialyl-Lewis (x), expression of 
fascin, expression of PR6 and P16INK4. 
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Tumours with allelic loss of chromosome 18q and loss of claudin-1 
(tight junction –associated protein) have poor prognosis.(79)(80) Tumours 
with HLA-DR expression, Bcl-2 protein expression  and TGF-beta1 
mutations have favourable outcome.
(81)(82) 
LYMPH NODE INVOLVEMENT : 
Lymph node involvement has a decreased survival rate. When 
nodes involved are other than those nodes which are close to the tumour 
indicates poor prognosis.
(83) 
 Worse is the prognosis when more number 
of lymph nodes are involved . 
PATTERN OF LYMPH NODE REACTION : 
When there are reactive changes produced by cell-mediated 
immune response it indicates good prognosis. 
STAGING AND GRADING : 
Staging and grading are very important predictors for prognosis. 
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MATERIALS AND METHODS 
STUDY DESIGN : 
           Prospective study.  
PLACE OF STUDY : 
 Department of Pathology, Coimbatore Medical College Hospital, 
Coimbatore. 
STUDY PERIOD : 
 July 2014 – July 2015 
INCLUSION CRITERIA : 
1.  All resected colorectal specimens received in Department of 
Pathology   
2.  Well fixed adequate tissues.  
EXCLUSION CRITERIA  
1. Inappropriately fixed specimens.  
         Sections of  four micron  thickness  were cut on to  coated slides . 
The slides are then incubated at 58 degrees overnight. The initial sections 
which were cut were stained with hematoxylin and eosin stain.  
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METHOD OF HEMATOXYLIN AND EOSIN STAINING  
REAGENTS USED:  
1. Erhlich’s Hematoxylin solution  
2. 1% Eosin Y solution  
3. 1% Acid alcohol solution  
PROCEDURE  
1. Sections deparaffinized in xylene by immersing for 30 seconds. 
2. Sections are then placed in Isopropyl alcohol for 15 minutes. 
3. Wash in running tap water. 
4. Stain the sections for 10 to 15 minutes with Erhlich’s  Hematoxylin 
solution. 
5. Wash in running tap water. 
6. Differentiate with acid alcohol 1% solution-two to three dips. 
7. Blueing is done for 10 minutes. 
8. Counterstain is done with eosin 1 % solution – 3 to 4 dips. 
9. Wash in tap water. 
10. Sections are air-dried.  
11. Dip in xylene and mount in DPX.  
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The sections stained with hematoxylin and eosin are studied and 
based on the histomorphological features, a diagnosis is obtained. 
IMMUNOHISTOCHEMISTRY : 
METHOD : 
Two Step indirect technique.  
PRINCIPLES OF IMMUNOHISTOCHMISTRY : 
          The principle of this technique is detection of antigens expressed in 
the cells and tissues and is done with two step process.  
1. Primary antibody using specific epitopes is bound to antigens.  
2. The antigen-antibody binding is then detected by calorimetric 
reaction.  
REAGENTS : 
1.  Peroxide Block : 3% hydrogen peroxide in water.  
2.  Power block:  contains casein and properity additives with 15mM     
sodium azide in PBS. It is a protein blocking reagent and it is     
highly effective. 
3.  Chromogen : DAB-33’ diaminobenzidine.  
53 
 
4.  Liquid DAB substrate : Tris buffer which contains peroxides and    
stabilizers.  
5.  Super enhancer reagent. 
6.  Counterstain with Meyer’s Hematoxylin.  
7.  Buffer solutions 
CITRATE BUFFER (pH 6.0) 
Trisodium Citrate  : 2.94 grams 
Distilled water : 1000 ml 
IN HCL  : 5 ml 
TRIS EDTA : (pH 9.0)  
TRIS buffer salt : 6.05 grams 
Disodium EDTA : 0.744 grams 
Distilled water : 1000ml 
TRIS BUFFER(pH 7.6) 
TRIS buffer salt : 0.605 grams 
Sodium Chloride : 8 grams 
Distilled water : 1000 ml 
IN HCL  : 3 ml 
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PROCEDURE : 
1. Sections are deparaffinized for 30 minutes in xylene 
2. Absolute alcohol for 5 minutes with two changes 
3. Wash in running tap water for 10 minutes 
4. Rinse for 5 minutes in distilled water 
5. Antigen retrieval is done in microwave by keeping the slides in it 
with appropriate buffer solutions  
          Medium : 10 minutes and high-10 minutes  
6. Cool the sections to room temperature  
7. Rinse in distilled water 
8. TBS buffer wash for 5 minutes with 2 changes 
9. Peroxide block for 10 minutes 
10. TBS buffer wash for 5 minutes with 2 changes 
11. Treat with power block for 10 minutes 
12. Cover the sections with primary antibody (supplied from 
DAKOCYTOMATION) 
13. TBS buffer wash for 5 minutes with 2 changes 
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14. Super enhancer for 30 minutes 
15. TBS buffer wash – 5 minutes 2 changes  
16. Poly HRP reagent for 30 minutes 
17. TBS Buffer wash for 5 minutes with 2 changes 
18. DAB Chromogen and substrate buffer for 5 to 8 minutes.   
19. TBS Buffer wash for 5 minutes -2 changes 
20. Wash in running tap water for 5 minutes  
21. Counterstain for 1 minute with Mayers Hematoxylin 
22. Tap water wash for 5 minutes 
23. Air dry and mount in DPX 
Positive Control for HER-2/neu includes breast carcinoma slides 
that is HER-2/neu immunoreactive. Negative control was also run each 
time.  
Immunohistochemical Evaluation  
 Sections are examined under high power objective for positive 
immunoreactivity. Positivity is considered when the neoplastic cells have 
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cytoplasmic, membranous or membranous and cytoplasmic golden brown 
staining. Semiquantitative scoring was carried out.  
Grading of intensity of staining  
         0 - Absent 
 1 - Weak 
 2 - Moderate 
 3 - Strong 
Percentage of positive tumour cells: 
 +1 - 10-40% of cells are positive 
 +2 - 41-70% of cells are positive 
 +3 - >70 % of cells are positive.   
HER-2/neu was considered positive if >10% of cells have strong 
immunostaining or >50% of cells show moderate staining.  
Data : 
 Tumour was subtyped using H & E sections according to WHO 
classification. Patient age, gender and HER-2/neu status was determined 
and expressed.  
57 
 
Statistical analysis : 
 For analysis SPSS software version was used and the variables 
expressed as percentage of number (%). For statistical comparisons 
Chisquare tests was employed. p Value <0.05 was considered statistically 
significant.  
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OBSERVATION AND RESULTS 
      The present study is a prospective study conducted in the 
Department of Pathology, Coimbatore Medical college Hospital. A total 
of 30 cases of colorectal adenocarcinoma specimens received over the 
period of July 2014 to July 2015 were studied. 
        Ethical clearance was obtained from Ethics committee of 
Coimbatore Medical College and Hospital,Coimbatore. 
        Histomorphological and immunohistochemical pattern of expression 
were  studied,analysed and compared with the literature. 
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TABLE 1 
AGE WISE DISTRIBUTION OF COLORECTAL 
ADENOCARCINOMAS (n=30) 
 
AGE CASES PERCENTAGE 
31-50 7 23% 
51 – 70 20 67% 
> 70 Yrs 3 10% 
Total  30 100% 
 
        In the above frequency table, it was observed that the incidence of 
colorectal carcinomas was high (67%) in the age group of 51-70 years, 
followed by the age group of 31-50 years (23%), and >70 years (10%). 
Patients age ranges from 34-80 years. Mean age is 58.6+/-24.6 years.   
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CHART 1 
AGE DISTRIBUTION OF COLORECTAL 
ADENOCARCINOMAS (n=30) 
 
 
 
 
 
 
 
                                       
From the above bar chart it is observed that the incidence of 
colorectal carcinomas was high (67%) in the age group of 51-70 years, 
followed by the age group of 31-50 years (23%), and  >70 years (10%). 
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TABLE 2 
SEX WISE DISTRIBUTION OF COLORECTAL          
ADENOCARCINOMA( n=30) 
SEX CASES PERCENTAGE 
MALE 21 70% 
FEMALE 9 30% 
Total  30 100% 
 
CHART 2 
 
         It was observed in the present study that the incidence of colorectal  
malignancy was comparatively high in males (70%) than in females 
(30%), with a male to female ratio of  2.3: 1 
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TABLE 3 
ANATOMICAL SITEWISE DISTRIBUTION OF COLORECTAL 
MALIGNANCY (n=30) 
 
LOCATION CASES PERCENTAGE 
RIGHT COLON 6 20% 
LEFT COLON 14 47% 
RECTUM 10 33% 
Total 30 100% 
      
          
 It was observed from the above frequency table, among 30 cases 
studied the incidence of colorectal malignancy was comparatively high in 
left colon (47%) followed by rectum (33%) and right colon (20%). 
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CHART 3 
ANATOMICAL SITEWISE DISTRIBUTION OF COLORECTAL 
MALIGNANCY (n=30)  
 
 
 
From the above pie diagram it is observed that colorectal 
malignancy was comparatively high in left colon (47%) followed by 
rectum (33%) and right colon (20%). 
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TABLE 4 
INCIDENCE OF VARIOUS SUBTYPES OF COLORECTAL 
ADENOCARCINOMA (n=30) 
 
TYPES CASES PERCENTAGE 
CONVENTIONAL 25 83.30% 
MUCINOUS 4 13.40% 
SIGNET RING CELL 1 3.30% 
Total 30 100% 
 
             It is observed from the above frequency table that conventional 
adenocarcinoma was 83.3% followed by mucinous adenocarcinoma 
13.4% and signet ring cell carcinoma 3.3%. 
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                                                   CHART 4 
INCIDENCE OF VARIOUS SUBTYPES OF COLORECTAL 
ADENOCARCINOMA (n=30) 
 
 
 
                In the present study among the many subtypes in colorectal 
adenocarcinoma only three subtypes was observed. Among the three 
subtypes, conventional adenocarcinoma (83.3%) was most common 
followed by mucinous adenocarcinoma (13.4%) and signet ring cell 
carcinoma (3.3%). 
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                                                TABLE 5 
INCIDENCE OF GRADES OF CONVENTIONAL 
ADENOCARCINOMA (n=25) 
GRADE CASES PERCENTAGE 
GRADE I 13 52% 
GRADE II 10 40% 
GRADE III 2 8% 
Total  25 100% 
 
CHART 5 
 
              It was observed that among twenty five cases  of conventional 
adenocarcinoma, well differentiated (grade I) was 52%, moderately 
differentiated (grade II) was 40% and poorly differentiated (grade III)  
was  8%. 
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TABLE 6 
HER-2/neu POSTIVITY IN COLORECTAL 
ADENOCARCINOMAS (n=30) 
HER2/neu CASES PERCENTAGE 
POSITIVE 20 67% 
NEGATIVE 10 33% 
Total  30 100% 
 
CHART 6 
 
 
          In the present study it was observed that HER-2/neu positive cases 
are 20 (67%)   and negative cases are 10 (33%). 
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TABLE  7 
AGE WISE DISTRIBUTION OF HER-2/ neu  EXPRESSION 
HER2/neu 
AGE -VE +1 +2 +3 +VE (%) 
31-50 3 (43%) 2 0 2 57% 
51 – 70 7 (35%) 4 3 6 65% 
> 70 Yrs   0 1 0 2 100% 
Total  10 7 3 10   
 
         In the current study out of 30 cases 7 cases were seen in the age 
group of 31-50 years of which 4 (57%) were HER-2/neu positive  and  3 
(43%) were negative. 20 cases were in the age group of  51-70 years of 
which  13(65%)  were HER-2/neu positive  and 7(35%) were negative. 3 
cases were in the age group of > 70 years of which  all the 3(100%) were 
HER-2/neu positive. These results were analysed using Chi-square 
analysis and found to be statistically significant with a p value of 0.03. 
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CHART  7 
AGE WISE DISTRIBUTION OF HER-2/ neu  EXPRESSION 
 
  
  
          In this clustered column diagram it is seen that HER-2/neu 
positivity was higher in age group >70 years in which all the 
3(100%) cases showing positivity  followed  by  51-70 years  
showing  65% positivity and 31-50 years showing 57% positivity. 
These results were analysed using chi-square analysis and found to 
be statistically significant. 
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TABLE  8 
SEX WISE DISTRIBUTION OF HER-2/ neu  EXPRESSION 
HER2/neu 
SEX -VE +1 +2 +3 +VE(%) 
MALE 10 (48%) 4 3 4 52% 
FEMALE   0 3 0 6 100% 
Total  10 7 3 10 
 
 
            In the present study out of 21 males,11 cases (52%) were HER-
2/neu positive and 10 cases were HER-2/neu negative. Whereas among 9 
females all of them(100%) were HER-2/neu positive.Chi square analysis 
showed a p value < 0.05 which is statistically significant.  
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CHART  8 
SEX WISE DISTRIBUTION OF HER-2/ neu  EXPRESSION 
 
 
 
           It is  seen from the above clustered column diagram that 
HER-2/neu positivity  was significantly higher in females (100%) 
than in  males in which HER-2/neu  positive was 52% and negative 
was 48%. These observations were statistically significant.(p<0.05) 
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TABLE  9 
HER-2/ neu  EXPRESSION IN VARIOUS LOCATIONS 
 
From the above table HER-2/neu positivity was higher in right 
colon with 5 cases (83%) out of 6 cases, followed by rectum with HER-
2/neu positivity in 7 cases (70%) out of 10 cases and left colon with 
HER-2/neu positivity in 8 cases (57%) out of 14 cases. Chi square 
analysis showed a stastically insignificant result. (p>0.05) 
 
 
 
 
HER-2/neu 
SITE -VE +1 +2 +3 +VE(%) 
Right Colon 1 (17%) 1 1 3 83% 
Left Colon 6 (43%) 5 1 2 57% 
Rectum 3 (30%) 1 1 5 70% 
Total 10 7 3 10   
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CHART  9 
HER-2/ neu  EXPRESSION IN VARIOUS LOCATIONS 
 
 
 
             As depicted in above clustered cylinder column, HER-
2/neu immunoreactivity was expressed  in right colon by 83% 
followed by rectum by 70% and left colon by 57%.Chi square 
analysis showed a statistically  insignificant result.(p>0.05) 
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TABLE  10 
HER-2/ neu  EXPRESSION IN VARIOUS TYPES 
 
HER2/neu 
TYPES -VE +1 +2 +3 +VE(%) 
CAC 6 (24%) 7 3 9 76% 
MAC 3 (75%) 0 0 1 25% 
SRCC 1 (100%) 0 0 0 0% 
Total 10 7 3 10   
 
As seen in the above table, HER-2/neu positivity was 76% in 
conventional adenocarcinoma followed by mucinous adenocarcinoma 
showing 25% HER-2/neu positivity. Only one case of signet ring cell   
carcinoma was observed which was HER-2/neu negative.These results 
were statistically insignificant.(p>0.05) 
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CHART  10 
HER-2/ neu  EXPRESSION IN VARIOUS TYPES 
 
 
          In the present study as seen from the bar chart, conventional 
adenocarcinoma showed 76% HER-2/neu positivity, mucinous 
adenocarcinoma showed 25% HER-2/neu positivity. Signet ring 
cell carcinoma was seen in only one case which is HER-2/neu 
negative. Chisquare analysis was statistically insignificant.(p>0.05) 
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TABLE  11 
HER-2/ neu  EXPRESSION IN VARIOUS GRADES 
 
HER2/neu 
GRADE -VE +1 +2 +3 +VE(%) 
I 3 (23%) 4 1 5 77% 
II 3 (30%) 3 1 3 70% 
III 0 0 1 1 100% 
Total 6 7 3 9   
 
It is observed from the above frequency table,out of 13 grade I 
tumours HER-2/neu positivity was observed in 10 cases(77%). In grade II 
tumours out of 10 cases, 7 cases (70%) showed HER-2/neu positivity.2 
cases of grade III tumours were observed of which both (100%) showed 
HER-2/neu positivity. These observations were statistically significant. 
(p<0.05) 
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CHART  11 
HER-2/ neu  EXPRESSION IN VARIOUS GRADES 
 
 
 
As seen from the bar chart, HER-2/neu positivity was 77% in grade 
I tumours, 70% in gradeII tumours and 100% in gradeIII tumours. Chi 
square analysis found to be statistically significant.(p<0.05) 
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TABLE  12 
HER-2/ neu  EXPRESSION IN LYMPHNODE METASTASES 
HER2/neu 
LYMPHNODE -VE +1 +2 +3 +VE(%) 
Metastases 0 2 3 3 100% 
Reactive 3 (43%) 3 0 1 57% 
NIL 7 (47%) 2 0 6 53% 
Total 10 7 3 10 
  
              In the present study lymphnode metastases was observed in 8 
cases in which all 8 cases(100%) showed HER-2/neu  postivity. Out of 7 
cases with  reactive nodes  4 cases(57%) were HER-2/neu positive.In 15 
cases no nodes were recovered. These observations were statistically 
significant.(p<0.05) 
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CHART  12 
HER-2/ neu  EXPRESSION IN LYMPHNODE METASTASES 
 
 
 
It is observed from the above clustered column diagram HER-
2/neu postivity was seen in all the 8 cases(100%) which showed 
lymphnode metastases. In the 7 cases with  reactive nodes, 4 cases(57%) 
showed HER-2/neu postivity.Chi square analysis was statistically 
significant(p<0.05) 
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TABLE  13 
HER-2/ neu  PATTERN OF STAINING 
 
PATTERN 
GRADE 
I II III 
CYT 9 (90%) 7 (100%) 0 
MEMB&CYT 1 (10%) 0 2 (100%) 
Total 10 7 2 
 
         It is observed from the above table, cytoplasmic positivity was seen 
in 9 cases (90%) of grade I tumours and 7 cases (100%) of grade II 
tumours. Membranous and cytoplasmic positivity was seen in 1 case 
(10%) of grade I tumour and 2 cases (100%) of grade III tumours. These 
results were statistically significant. (p<0.002) 
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CHART  13 
HER-2/ neu  PATTERN OF STAINING 
 
 
 
            In the present study cytoplasmic postivity was seen in 90% of 
grade I tumours  and 100%  of grade II tumours.Membranous and 
cytoplasmic positivity was observed in 10% of grade I tumours and 100%  
of  grade III tumours. Chi square analysis was found to be statistically 
significant. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
COLOUR PLATES 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Well differentiated adenocarcinoma of colon H & E(10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Moderately differentiated adenocarcinoma of colon H & E(10X) 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Poorly differentiated adenocarcinoma of colon  H & E(10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Mucinous adenocarcinoma of colon H & E(10X) 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Diffuse (+3)HER-2/neu positivity in Grade I adenocarcinoma showing 
membranous and cytoplasmic staining(10X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Diffuse (+3)HER-2/neu positivity in Grade I adenocarcinoma showing       
membranous and cytoplasmic staining (40X) 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Diffuse (+3)HER-2/neu positivity in Grade II  adenocarcinoma showing 
cytoplasmic staining (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8. Diffuse (+3)HER-2/neu positivity in Grade II adenocarcinoma showing 
cytoplasmic staining (40X) 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.9. Diffuse (+3)HER-2/neu positivity in Grade III adenocarcinoma  showing 
membranous and cytoplasmic staining (10X) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10. Diffuse (+3)HER-2/neu positivity in Grade III  adenocarcinoma showing 
membranous and cytoplasmic staining(40X) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. HER-2/neu positivity in mucinous adenocarcinoma showing cytoplasmic 
staining (10X) 
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DISCUSSION 
Colorectal cancer is one of the most common leading causes of 
cancer related mortality and account for approximately 9% of all human 
cancers.  Eventhough the tumour is diagnosed by histopathology and 
tumour grade and stage are strong prognostic factors, identification of 
newer prognostic indicators such as expression of various immunological 
markers arises depending on which clinical behaviour and treatment 
differs.  Various literature have shown that detection of HER-2/neu is a 
useful marker and is used to predict the outcome of colorectal cancers. 
In the present study, expression of HER-2/neu was studied in 
colorectal carcinomas and its correlation with other clinicopathological 
variables were analysed. 
Thirty cases of colorectal carcinomas were included in the study.  
The age of patients ranges from 34 to 80 years with mean age 58.6+/- 
24.6 years (TABLE 1).  This is in accordance with the results by 
Manmeet Kaur Gill et al (2011) in which mean age was 53.9 years with a 
range of 19 to 88 years.
(3)
  Similar studies conducted by Ghaffarzadegan 
et al (2006) and Neklason et al (2008) showed mean age of 56.8 and 55.7 
years respectively .
(7)(84) 
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Out of 30 cases studied, males were 21   outnumbering females 
who were 9 in number (ie) males constituted around 70% and females 
were 30%.  The male:female ratio is 2.3:1 (TABLE 2).  This is similar to 
the study by Dalal a.elwy et al (2012) in which out of 50 cases 60% were 
males and 40% were females with a male to female ratio 1.5:1.
(8)
 Study 
by Schuell et al (2006) also showed a male preponderance.
(85) 
Out of 30 cases studied, involvement of right colon is seen in 20% 
and 80% in left colorectal region (Table 3). Tavangar and associates 
(2005) also observed similar results with left colorectal region 
involvement constituting 54.4% and right colon constituting 45.6%.
(86) 
The study includes following types of adenocarcinomas, 
conventional, mucinous and signet ring cell carcinoma. Of these 
conventional adenocarcinoma was most common constituting about 
83.3% followed by mucinous adenocarcinoma constituting 13.40% and 
signet ring cell carcinoma 3.3% (TABLE 4).  A Study by Manmeet Kaur 
Gill et al (2011) showed similar results as in the present study with 
conventional adenocarcinoma constituting  77.5% followed by mucinous 
adenocarcinoma 17.5% and 2.5% of each signet ring cell carcinoma and 
carcinoid.
(3) 
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Out of 30 cases, 25 cases were conventional adenocarcinoma of 
which 52% was grade I tumour, 40% was grade II tumour and 8% was 
grade III tumours.(Table 5).  Similar results were observed in studies by 
Manmeet kaur Gill et al and and Ghaffarzadegan et al. 
Out of total thirty cases studied 20 cases were HER-2/neu positive 
and 10 cases were HER-2/neu negative which constitutes 67% and 33% 
respectively (TABLE 6).  Out of 67% positive cases 31% showed +3 
staining, 13% showed +2 staining and 23% showed +1 staining for HER-
2/neu.  The staining intensity in most cases was moderate (45%) to strong 
(19.5%) with weak staining in only one case (2.5%). 56.9% of cases 
showed cytoplasmic positivity and 10.1% showed membranous and 
cytoplasmic staining.  No case showed pure membranous pattern of 
staining. 
Similar results were observed in a study by Manmeet Kaur Gill et 
al (2011) in which HER-2/neu positivity constituted about 65% of which 
cytoplasmic staining was seen in 57.5% and membranous-cytoplasmic 
staining in 7.5%.  As in our study, no case showed a pure membranous 
pattern of staining.  30% of cases showed +3 staining, 12.5% showed +2 
staining and 22.5% showed +1 staining. Intensity of staining was 
moderate (50%) to strong (12.5%) with weak staining in one case 
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(2.5%).
(3)
  In another study by Ghaffarzadegan et al (2006) in 69 cases, 
HER-2/neu positivity was seen in 59.4% with cytoplasmic staining, 
membranous and cytoplasmic staining in 34.1% of cases.
(84)
  Another 
study by Half et al (2003) cytoplasmic staining seen in 65.9% and 
membranous staining in 5% of cases.
(87)
 Our study correlates well with all 
the above studies. 
In contrast to our study Nathanson et al (2003) studied HER- 2/neu 
expression and gene amplification in 139 cases and found only five cases 
(3.6%) showed HER-2/neu positivity.  The reason for this low positivity 
might be they have considered only membranous staining.
(88) 
HER-2/neu positivity was analysed with the age of the patients.  
Out of 30 cases, 7 cases were in age group of 31-50 years of which 4 
(57%) were HER-2/neu positive, 20 cases in age group of 51-70 years of 
which 13(65%) were HER-2/neu positive and 3 cases in age group >70 
years in which all the 3(100%) were HER-2/neu positive.  It was seen that 
as the age of the patients increased, the percentage positivity of HER-
2/neu  staining  also increased.  These results were analysed by chi-square 
test analysis and was found to be statistically significant (P<0.03) 
(TABLE 7).  Similar results were seen in study by Manmeet Kaur Gill et 
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al (2011) in which HER-2/neu percentage positivity was increased as age 
increased with a p value of 0.002.
(3) 
HER-2/neu positivity was analysed with sex of the patients. Of the 
total 30 cases, 21 were males out of which HER-2/neu positivity is seen 
in 11 cases which constituted around 52%. 9 cases were females of which 
all of them (100%) showed HER-2/neu positivity. (TABLE 8). In a study 
by Gruenberger et al (2006) percentage positivity was more in males than 
in females which was in contrast to our study.
(89)
  
In the present study, out of 30 cases involvement of right colon was 
seen in 6 cases of which 5 cases (83%) showed HER-2/neu positivity.  
Left colon involvement was seen in 14 cases of which 8 cases (57%) 
showed HER-2/neu positive.  Rectum was involved in 10 cases out of 
which 7 cases (70%) showed HER-2/neu positivity.  Chi-square analysis 
showed a statistically insignificant relation between HER-2/neu 
expression and site of tumour.(p>0.05). (TABLE 9).  These results were 
similar to other study by Mohammadi et al (2011) in which no 
statistically significant correlation was obtained between HER-2/neu 
expression and site of tumour.
(90) 
Types of colorectal adenocarcinoma observed in the present study 
were conventional adenocarcinoma which showed HER-2/neu positivity 
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by 76% followed by mucinous adenocarcinoma 25%. Only 1 case of 
signet ring cell carcinoma was observed which was HER-2/neu negative.  
Chi-square test showed a p value >0.05 which was statistically 
insignificant (TABLE 10). Similar results were observed in a study by 
Kavanagh et al (2009) in which there was no statistically significant 
relation was seen between HER-2/neu expression and histologic types.
(91)
  
In the present study, Grade I tumours showed 77% of HER-2 neu 
positivity followed by grade II tumours constituting about 70% and grade 
III tumours showing 100% positivity for HER-2/neu.(TABLE 11).  These 
results were similar to studies by Manmeet Kaur Gill et al (2011) and 
Hay et al (2003) in which they found significant correlation between 
HER-2/neu and grade.  They also observed that grade III tumours showed 
100% HER-2/neu positivity.
(3) 
In present study, membranous and cytoplasmic positivity was seen 
100% in grade III tumours than in grade I tumours which constitutes 
10%.  A study by Shoroq Mohammed Abas al (2014) also showed 100% 
membranous and cytoplasmic HER-2/neu positivity in grade III tumours 
more than grade I.
(92)
  Similar results were also observed by 
Ghaffarzadegan et al (2006).
(84)
  In the present study, out of 30 cases, 
only in 15 cases nodes were recovered and 8 out of them were metastatic.  
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All the 8 cases with metastatic nodes were positive for HER-2/neu 
staining.  Out of 7 reactive nodes only 4 cases was HER-2/neu positive.  
These results were statistically significant (p<0.05) and that there is 
correlation between HER-2/neu staining and lymph node metastases 
(TABLE 12).  This was similar to study by Manmeet Kaur Gill et al 
(2011) in which out of 40 cases in 20 cases lymphnodes were recovered 
and ten were metastatic and all the ten cases were HER-2-neu positive.
(3)
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SUMMARY AND CONCLUSION 
Colorectal carcinomas are one among the most common human 
malignancies. Most of the tumours are diagnosed, classified and graded 
with H & E stained sections. Various immunological markers are 
expressed in colorectal malignancies and these are studied to identify 
targeted therapy and to increase the survival of the patients. HER-2/neu 
overexpression indicates higher tumour grade and stage and a monoclonal 
antibody (Trastuzumab) directed against HER-2 has increased survival in 
many tumours. Hence HER-2/neu expression in colorectal carcinomas are 
being studied extensively. 
In the present study thirty cases of colorectal adenocacinomas were 
included. HER-2/neu positivity is seen in 67% of the cases. HER-2/neu 
expression increased as age of the patients increased. HER-2/neu 
expression was higher in females (100%) compared to males. Location 
and type of tumour had no correlation with HER-2/neu. HER-2/neu 
staining was higher in grade III tumours(100%) when compared to 77% 
in grade I tumours showing a positive correlation of HER-2/neu with 
grade. This suggests as the tumour grade increases HER-2/neu positivity 
increases. There was 100% HER-2/neu positivity in metastatic nodes 
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showing a positive correlation. Membranous and cytoplasmic staining 
was higher (100%) in grade III tumours. 
From the study it is concluded that rate of HER-2/neu expression in 
colon carcinoma is high. Most cases had cytoplasmic staining but 
membranous and cytoplasmic staining was seen in higher grades. Hence 
targeted therapy could be helpful in patients with high grade and with 
lymph node or distant metastases. Because of many pitfalls in 
immunohistochemistry, further studies such as gene amplification studies 
involving larger number of patients are needed to assess HER-2/neu 
expression in colorectal carcinomas and to develop new targeted therapy. 
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ANNEXURE I 
ANNEXURE I 
PROFORMA 
COIMBATORE  MEDICAL  COLLEGE 
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
Particulars of the patient: 
Name           :                               IP/OP number   : 
Age(Years)  :                               Ward No           : 
Sex               :                               Occupation       :  
Address        : 
Presenting Complaints and Duration: 
Abdominal pain 
Change in bowel habits with alternate diarrhea and constipation 
Hematochezia  
Easy fatiguability  
Fever  
Loss of weight/Loss of appetite 
Past history: 
History of previous surgeries 
History of previous irradiation 
Family history of any malignancy 
Personal history: 
Dietary habits 
Smoker +/- 
Alcoholic +/- 
General Physical  Examination: 
Built                   :                           Febrile/afebrile         : 
Nourishment       :                           Pallor                       : 
Conscious           :                           Jaundice                   : 
Weight                :                           Cyanosis                  :   
Pulse Rate           :                          Clubbing                  : 
Respiratory rate  :                           Lymphadenopathy  : 
  
 
Systemic Examination : 
RS     :                                   P/A   : 
CVS  :                                   CNS  : 
Digital Rectal Examination:         
Radiological Findings: 
X-Ray          : 
CT                : 
MRI             : 
Colonoscopic Findings   : 
Microscopic Findings: 
Histopathological Diagnosis    : 
Immunohistochemistry             : 
FINAL DIAGNOSIS 
 
 
  
CONSENT FORM 
         Dr.N.Vani,postgraduate student in the department of 
pathology,Coimbatore Medical  College is conducting a study on “HER 
2 neu EXPRESSION IN COLORECTAL ADENOCARCINOMA 
AND ITS CORRELATION WITH CLINICOPATHOLOGIC 
VARIABLES”.  Colectomy done for various colorectal lesions are 
received in pathology department and  are processed and examined under 
a microscope to obtain diagnostic information or is tested for other 
studies. I have been informed to my satisfaction regarding the nature of 
procedure. The data used herein may be used for research and 
publication. 
 
Name            : 
Place             : 
Signature      : 
 
 
 
 
xg;g[jy; gotk; 
 
bgah;   : 
 
taJ   : 
 
ghypdk;  : 
 
Kfthp  : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; neha; Fwpapay; kUj;jt 
Jiwapy; gl;;l nkw;gog;g[ gapYk; khztp kU.e.thzp mth;fs; 
nkw;bfhs;Sk; “bgU';Fly; g[w;Wnehapy; Her-2/neu tpd; btspg;ghl;oid 
mwpjy;” gw;wpa Ma;tpy; bra;Kiw kw;Wk; midj;J tpsf;f';fisa[k; 
nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J 
bfhs;s rk;kjpf;fpnwd;. 
,e;j ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; 
,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
 
,lk; : 
njjp :        ifbahg;gk; / nuif 
 
 
 
  
 
                                     
 
 
 
 
 
 
                                     ANNEXURE II 
ANNEXURE - II 
MASTER CHART 
 
S.NO AGE SEX IPNO HPENO SITE TYPES GRADE HER2NEU LN METS 
1 47 M 45521 304/14 LC CAC II 1+ METS 
2 67 M 3482 305/14 REC CAC I 1+ RFH 
3 65 M 14203 950/14 LC CAC II 0 - 
4 54 M 10650 1053/14 REC CAC I 3+ METS 
5 34 M 11614 1209/14 REC CAC I 0 - 
6 53 F 23095 1470/14 REC CAC II 3+ - 
7 78 M 27178 2206/14 LC CAC I 1+ - 
8 60 M 46997 2760/14 RC CAC III 2+ METS 
9 58 M 51336 3079/14 LC CAC II 0 - 
10 54 M 51403 3215/14 LC CAC II 1+ RFH 
11 65 M 56708 3227/14 LC CAC III 3+ METS 
12 70 M 62254 3530/14 LC CAC II 0 RFH 
13 67 F 76055 4210/14 RC CAC II 3+ - 
14 47 M 76031 4211/14 LC CAC I 0 - 
15 58 F 81839 262/15 REC CAC I 3+ - 
16 62 F 1684 280/15 RC CAC II 1+ - 
17 40 M 5143 324/15 LC MAC - 0 RFH 
18 50 F 81981 330/15 LC CAC I 1+ METS 
19 60 M 5785 405/15 RC MAC - 0 - 
20 60 F 10825 702/15 REC CAC I 3+ - 
21 65 M 7654 705/15 LC CAC II 2+ METS 
22 42 F 16141 859/15 RC CAC II 3+ RFH 
23 40 F 22848 1194/15 RC MAC - 3+ - 
24 70 M 32821 1805/15 REC CAC I 0 RFH 
25 60 M 36174 1911/15 LC MAC - 0 - 
26 64 M 38268 2136/15 REC CAC I 2+ METS 
27 72 M 41223 2187/15 LC CAC I 3+ METS 
28 55 M 43589 2274/15 REC SRCC - 0 - 
29 62 F 46634 2460/15 LC CAC I 1+ RFH 
30 80 M 51147 2499/15 REC CAC I 3+ - 
KEY WORDS TO MASTER CHART 
 
LC          -     Left colon 
RC          -     Right colon 
REC        -     Rectum 
CAC        -     Conventional adenocarcinoma  
MAC       -      Mucinous adenocarcinoma 
SRCC      -      Signet ring cell carcinoma 
METS      -      Metastases 
RFH         -      Reactive follicular hyperplasia 
 
 
 
 
 
 
  
 
 
                                   
 
 
 
 
 
                                    ANNEXURE III 
 
ANNEXURE III-LIST OF ABBREVATIONS 
H & E              -  Hematoxylin and Eosin 
HER-2/neu      -  Human Epidermal growth factor Receptor 
CK                   -   Cytokeratin 
CEA                 -   Carcino Embryonic Antigen 
HCG                 -   Human Chorionic Gonadotrophin 
PLAP                -   Placental Alkaline Phosphatase 
APC                  -   Adenomatous Polyposis Coli 
TAG 72            -   Tumour Associated Glycoprotein 
ACF                  -   Aberrant Crypt Foci 
CAC                 -    Conventional  Adenocarcinoma 
MAC                -     Mucinous Adenocarcinoma 
SRCC               -    Signet Ring Cell Carcinoma 
METS              -     Metastases 
RFH                 -     Reactive Follicular Hyperplasia 
CYT                 -     Cytoplasmic 
MEMB             -     Membranous 
